SAEVA Proceedings 2016 | Page 117

  practitioners will therefore use 3000 IU in the spring. Certainly, a proportion of mares will fail to respond as expected to hCG; this seems to be more common in older mares, mares treated repeatedly within a single breeding season, and mares that are treated too early in oestrus. In this latter respect, it is probably not sensible to stick slavishly to a follicle size of 35mm as the sole criterion for when to administer hCG. In a mare that normally ovulates a 50mm follicle and develops obvious endometrial oedema, it is preferable to wait until the oedema pattern is clear and the follicle is somewhat larger (e.g. 40-45mm) before administering the hCG. Conversely, it is not sensible to wait for a follicle to reach 35mm so that hCG can be administered before ordering chilled semen for a mare that has previously ovulated 30mm follicles. In mares that have previously failed to respond to hCG, older mares, or when ovulation needs to be induced earlier (e.g. 30mm follicle) than considered ideal (e.g. because chilled semen is only available on Saturday or the following Tuesday), a long-acting GnRH analogue is preferred as the ovulation induction agent. The GnRH analogue of choice in Europe is currently the deslorelin implant, Ovuplant™, primarily because it is the only such product officially registered; ovulation is anticipated 41 ± 3 h after subcutaneous introduction of the implant (McKinnon and McCue, 2012). The major disadvantage described when using Ovuplant as an ovulation inducing agent, is suppression of pituitary gonadotrophin secretion and a resulting inhibition of follicle development; fortunately, this suppression seems to be fairly transient (approx. 10 days: Johnson et al., 2002) and is therefore only really an issue in embryo donor mares. Moreover, the risk of ovarian suppression can be averted by placing the implant in the vaginal muscosa, where it can be easily located and removed once ovulation has been confirmed. While deslorelin is often considered to be more reliable and to yield a more predictable time of ovulation than hCG, there are still mares that fail to ovulate at the expected time (i.e. within 48h), or that develop an anovulatory haemorrhagic follicle. While they are not commonly used, short-acting GnRH preparations (e.g. buserelin) are also effective for inducing ovulation in mares, particularly if administered repeatedly (e.g. at 12 h intervals: Barrier-Battut et al., 2001). The author quite commonly uses twice daily injections of 20 mg buserelin to promote ovulation in mares that have failed to ovulate within 48 h of hCG administration. Chilled semen Within the Dutch AI network, if semen is ordered before 09:00 it will generally be delivered on the same day, and within 12 h after collection. For the majority of stallions, we aim to perform AI with chilled semen 15-40 h prior to ovulation (AI is performed in the afternoon, and the ovulation checks with respect to potential reordering in the morning); for some stallions, however, previous experience may result in a strong preference to ensure AI no more than 15 h prior to ovulation. In many cases, therefore, the AI protocol simply involves inducing ovulation and ordering semen for the following afternoon, which is fine if the mare is presented early in oestrus. However, mares are often presented late in oestrus (i.e. with a large soft follicle, little uterine oedema), and it is then prudent to order semen for the same day and either use 15-­‐18  February  2016      East  London  Convention  Centre,  East  London,  South  Africa     116